Indian J Pharm Close
 

Figure 1: (a) Left ventricular developed pressure (LVDP) and (b) coronary resistance (CR) from control group (n = 8), simultaneous type 2 diabetes and renal hypertension group receiving vehicle (DM2 + HTN-Veh) (n = 8), simultaneous type 2 diabetes and renal hypertension groups receiving oleuropein at 20 mg/kg/day (DM2 + HTN-Ole20) (n = 7), 40 mg/kg/day (DM2 + HTN-Ole40) (n = 6), or 60 mg/kg/day (DM2 + HTN-Ole60) (n = 8) at preischemia (preisch), and at 30 and 60 min of reperfusion. Data are presented as mean ± SEM. *Signifi cant difference (P = 0.05) from the control. Significant difference from the control (a; P = 0.03, b; P = 0.02, c; P = 0.01, d; P = 0.001). Significant difference from the DM2 + HTN-Veh (e; P = 0.05, f; P = 0.02, g; P = 0.01, h; P = 0.003, I; P = 0.001). Signifi cant difference from the DM2 + HTN- Ole20 (J; P = 0.05, k; P = 0.03, l; P = 0.009, o; P = 0.005, m; P = 0.003, n; P = 0.001)

Figure 1: (a) Left ventricular developed pressure (LVDP) and (b) coronary resistance (CR) from control group (<i>n</i> = 8), simultaneous type 2 diabetes and renal hypertension group receiving vehicle (DM2 + HTN-Veh) (<i>n</i> = 8), simultaneous type 2 diabetes and renal hypertension groups receiving oleuropein at 20 mg/kg/day (DM2 + HTN-Ole20) (<i>n</i> = 7), 40 mg/kg/day (DM2 + HTN-Ole40) (<i>n</i> = 6), or 60 mg/kg/day (DM2 + HTN-Ole60) (<i>n</i> = 8) at preischemia (preisch), and at 30 and 60 min of reperfusion. Data are presented as mean ± SEM. *Signifi cant difference (<i>P</i> = 0.05) from the control. Significant difference from the control (a; <i>P</i> = 0.03, b; <i>P</i> = 0.02, c; <i>P</i> = 0.01, d; <i>P</i> = 0.001). Significant difference from the DM2 + HTN-Veh (e; <i>P</i> = 0.05, f; <i>P</i> = 0.02, g; <i>P</i> = 0.01, h; <i>P</i> = 0.003, I; <i>P</i> = 0.001). Signifi cant difference from the DM2 + HTN- Ole20 (J; <i>P</i> = 0.05, k; <i>P</i> = 0.03, l; <i>P</i> = 0.009, o; <i>P</i> = 0.005, m; <i>P</i> = 0.003, n; <i>P</i> = 0.001)